Anne Lecocq
Senior Vice President and General Manager, Research & Development
Anne Lecocq is a seasoned life sciences executive with over 20 years of experience. She began her career in the pharmaceutical and generics industries, specializing in regulatory compliance and chemistry, manufacturing and controls (CMC), before joining Clarivate in 2008.
At Clarivate, Anne has held multiple leadership roles overseeing data and content strategy for Cortellis solutions spanning drug discovery, clinical trials, competitive intelligence, safety, and regulatory intelligence. In her current role as General Manager of the R&D Business, she drives product innovation and strategic growth for the Cortellis product suite, enabling biopharma organizations to accelerate the delivery of life-changing therapies to patients through actionable intelligence and advanced analytics.
Anne holds dual master’s degrees in Biotechnology & Chemistry and Regulatory Affairs. Based in Paris, France, she is passionate about leveraging her multidisciplinary expertise to advance global R&D efficiency through transformative intelligence.
Latest news
Clarivate Unveils Citation Laureates 2025 – Highlighting Nobel-Class Research with Global Impact
22 Researchers Recognized, Including First Citation Laureate Based in Mainland China London, U.K. September 25, 2025: Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the Citation…
Clarivate Announces the India Research Excellence – Citation Awards 2025
The 10th Edition to Honor Researchers and Institutions for Pioneering Contributions to Research London, U.K. September 19, 2025. Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced…
BioWorld by Clarivate Celebrates 35 Years of Trusted Biopharma and Medtech Journalism
Award-winning independent news and analysis continue to guide life sciences leaders through rapid scientific and market change London, U.K. — September 18, 2025 — BioWorld, published by Clarivate Plc (NYSE:CLVT),…